Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elixinol WellnessASX:EXL Days Sales Outstanding is 29.07 as of Dec. 2025, which is 31% below its 10-year median of 42.04. The stock has 7 warning signs investors should review. Among 946 Drug Manufacturers companies, Elixinol Wellness ranks better than 89.64% on this metric.
The historical rank and industry rank for Elixinol Wellness's Days Sales Outstanding or its related term are showing as below:
ASX:EXL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.53 Med: 42.04 Max: 63.44
Current: 31.53
During the past 8 years, Elixinol Wellness's highest Days Sales Outstanding was 63.44. The lowest was 31.53. And the median was 42.04.
ASX:EXL's Days Sales Outstanding is ranked better than 89.64% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.825
vs ASX:EXL: 31.53
Elixinol Wellness's Days Sales Outstanding
declined
from Dec. 2024 (39.20) to Dec. 2025 (29.07).
Elixinol Wellness (ASX:EXL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Elixinol Wellness Days Sales Outstanding Related Terms
Elixinol Wellness Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Elixinol Wellness's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EXL vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elixinol Wellness Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Elixinol Wellness's Days Sales Outstanding falls into.
Elixinol Wellness Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elixinol Wellness (ASX:EXL) has a Days Sales Outstanding of 29.07 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Elixinol Wellness and its competitors. This is 31% below median its historical median of 42.04. Over the past decade, Elixinol Wellness' Days Sales Outstanding has ranged from 31.53 to 63.44. According to the industry distribution chart, Elixinol Wellness ranks #98 out of 946 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is Elixinol Wellness' Days Sales Outstanding too high?
Elixinol Wellness' current Days Sales Outstanding of 29.07 is 31% below median its 10-year median of 42.04. Over the past 10 years, this metric has ranged from a low of 31.53 to a high of 63.44. The Drug Manufacturers industry median Days Sales Outstanding is 71.83. Elixinol Wellness' value of 29.07 is 59.5% below this industry median. Based on the distribution chart, Elixinol Wellness ranks #98 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Elixinol Wellness' Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixinol Wellness ranks #98 out of 946 companies for Days Sales Outstanding. This places Elixinol Wellness in the top 10% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.83. Elixinol Wellness' value of 29.07 is 59.5% below this benchmark. Historically, Elixinol Wellness' own Days Sales Outstanding has ranged from 31.53 to 63.44 over the past decade. While the company's 10-year median is 42.04 vs. the industry median of 71.83, Elixinol Wellness has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.83, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elixinol Wellness's current Days Sales Outstanding of 29.07 is 59.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Elixinol Wellness and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixinol Wellness's current Days Sales Outstanding is 29.07, which is 31% below median its own 10-year median of 42.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 65% below its estimated fair value. The current Days Sales Outstanding is 29.07, which is 31% below median its 10-year median of 42.04 and 59.5% below the Drug Manufacturers industry median of 71.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current Days Sales Outstanding is 29.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EXL has been successfully added to your 
